Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

PRESS RELEASE:Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potencyBEDFORD, Mass.–(BUSINESS WIRE)–February 24, 2017– Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy announced a newly published analysis from the company’s Phase 3 SpaceOAR System clinical trial. An abstract accepted at the ASCO 20